ATLANTA, Sept. 13, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota
Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, today announced that
management will host a conference call on Wednesday, September 14, 2016 at 4:30 p.m. ET to review the Company’s financial results
for the three month period and 2016 fiscal year ended June 30, 2016 and will provide an update on recent corporate developments.
The Company will issue a press release summarizing its financial results the same day, prior to the conference call.
In order to participate in the conference call, please dial (877) 312-5422 (domestic) or (253) 237-1122
(international) and refer to conference ID number 74878442. The live webcast can be accessed under the Investors section of the
Company’s website at www.aviragentherapeutics.com.
About Aviragen Therapeutics, Inc.
Aviragen Therapeutics is focused on the discovery and development of the next generation of direct-acting
antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The
Company has three product candidates in active clinical development: vapendavir, an oral treatment for human rhinovirus upper (HRV)
respiratory infections in moderate-to-severe asthmatics currently being evaluated in the Phase 2b SPIRITUS trial; BTA585, an oral
fusion protein inhibitor that has received Fast Track designation by the U.S. FDA, in Phase 2 development for the
treatment and prevention of respiratory syncytial virus (RSV) infections; and BTA074, a topical antiviral treatment in Phase 2
development for condyloma caused by human papillomavirus types 6 & 11. For additional information about the Company, please
visit www.aviragentherapeutics.com.
Contacts: Mark Colonnese Executive Vice President and Chief Financial Officer Aviragen Therapeutics, Inc. (678) 221-3381 mcolonnese@aviragentherapeutics.com Beth DelGiacco Stern Investor Relations, Inc. (212) 362-1200 beth@sternir.com
